Neuroblastoma other imaging findings
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]Haytham Allaham, M.D. [3]
Overview
Nuclear medicine studies used for diagnosis of neuroblastoma include fluorodeoxyglucose-18F positron emission tomography (18F- FDG PET) scan and metaiodobenzylguanidine (123I-MIBG) scintigraphy. 18F-FDG PET scan may distinguish stage 1 and 2 neuroblastoma from other differential diagnoses. 123I- MIBG scintigraphy distinguishes stage 3 and 4 neuroblastoma other differential diagnoses.
Other Imaging Findings
- Nuclear medicine
- Nuclear medicine studies used for diagnosis of neuroblastoma include fludeoxyglucose-18F positron emission tomography (18F-FDG PET) and metaiodobenzylguanidine (123I-MIBG) scintigraphy.[1][2][3]
- 18F-FDG PET scan may distinguish stage 1 and 2 neuroblastoma from other differential diagnosis.
- 123I-MIBG scintigraphy may distinguish stage 3 and 4 neuroblastoma from other differential diagnosis.
- 123I-MIBG scintigraphy is superior than 18F-FDG PET scan in detecting bone marrow metastases.
References
- ↑ Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL (2009). “123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma”. J Nucl Med. 50 (8): 1237–43. doi:10.2967/jnumed.108.060467. PMID 19617326.
- ↑ Denah R. Taggart, Myo M. Han, Alekist Quach, Susan Groshen, Wei Ye, Judith G. Villablanca, Hollie A. Jackson, Carina Mari Aparici, David Carlson, John Maris, Randall Hawkins & Katherine K. Matthay (2009). “Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (32): 5343–5349. doi:10.1200/JCO.2008.20.5732. PMID 19805691. Unknown parameter
|month=ignored (help) - ↑ Nadja C. Colon & Dai H. Chung (2011). “Neuroblastoma”. Advances in pediatrics. 58 (1): 297–311. doi:10.1016/j.yapd.2011.03.011. PMID 21736987.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH